FCCC LOGO Faculty Publications
Galsky MD , Balar AV , Black PC , Campbell MT , Dykstra GS , Grivas P , Gupta S , Hoimes CJ , Lopez LP , Meeks JJ , Plimack ER , Rosenberg JE , Shore N , Steinberg GD , Kamat AM
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
J Immunother Cancer. 2021 Jul;9(7)
PMID: 34266883    PMCID: PMC8286774    URL: https://www.ncbi.nlm.nih.gov/pubmed/34266883
Back to previous list
Abstract
A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
Notes
2051-1426 Galsky, Matthew D Balar, Arjun V Black, Peter C Campbell, Matthew T Dykstra, Gail S Grivas, Petros Gupta, Shilpa Hoimes, Christoper J Lopez, Lidia P Meeks, Joshua J Plimack, Elizabeth R Rosenberg, Jonathan E Shore, Neal Steinberg, Gary D Kamat, Ashish M Journal Article J Immunother Cancer. 2021 Jul;9(7):e002552. doi: 10.1136/jitc-2021-002552.